Form 4: Centessa Pharmaceuticals' General Counsel, Iqbal Hussain, Reports Stock Transactions

Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reports the acquisition and disposal of ordinary shares, including transactions under a Rule 10b5-1 trading plan.

Summary

• On May 1, 2025, Iqbal Hussain, General Counsel of Centessa Pharmaceuticals, reported transactions involving the company's ordinary shares.
• Hussain acquired 311 ordinary shares at a price of $5.84.
• Simultaneously, Hussain disposed of 311 ordinary shares at a price of $14.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024.
• Following these transactions, Hussain directly owns 105,386 ordinary shares and indirectly owns 5,500 ordinary shares through a spouse.
• Hussain also holds options to purchase 303,559 ordinary shares at an exercise price of $5.84.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. The use of a 10b5-1 plan indicates a pre-arranged strategy to avoid accusations of trading on inside information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the insider's trading activity, but the use of a 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates

Keywords

Centessa Pharmaceuticals, Iqbal Hussain, Form 4, Stock Transactions, Rule 10b5-1, Ordinary Shares, Share Options, CNTA, General Counsel